Roche's Genentech Provides Update On Phase III SKYSCRAPER-01 Study In PD-L1-High Metastatic Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech has provided an update on its Phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. The study did not meet its primary endpoint of improving progression-free survival in people with PD-L1-high metastatic non-small cell lung cancer.
August 23, 2023 | 5:57 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Roche's Genentech failed to meet the primary endpoint in its Phase III SKYSCRAPER-01 study, which could negatively impact the company's stock in the short term.
The failure of a Phase III study is a significant setback for any pharmaceutical company as it represents a major investment in terms of time and resources. This could potentially lead to a decrease in investor confidence and a drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100